DOI: 10.21088/ijnns.0975.0223.17225.5

International Journal of Neurology and Neurosurgery
Volume 17, Number 2 May-August 2025

REVIEW ARTICLE

Predictive Toxicology of Neurological Disorder Drugs: A Quantum Mechanics and Rational Design Approach

Maitreyi Pathak[1], Prachi Srivastava[2]

HOW TO CITE THIS ARTICLE:

Maitreyi Pathak, Prachi Srivastava. Predictive Toxicology of Neurological Disorder Drugs: A Quantum Mechanics and Rational Design Approach. International Journal of Neurology and Neurosurgery. 2025; 17(2): 102-109.

ABSTRACT

Developing safe and effective therapies for neurological disorders such as Alzheimer's, Parkinson's, and Epilepsy, is essential given that these can affect millions of people across the globe that result in significant challenge to healthcare system. Unfortunately, the development of neurological does drugs face a lack of abandonment owing to severe toxicity risks which include neurotoxicity, hepatotoxicity, and cardiotoxicity, drugs fail in the later stages of clinical trials due to unpredictable side effects, metabolic instability, poor bioavailability. Many drugs which are neurotoxic have a high risk of toxicity and predictive harmful effects. Prior to the commencement of clinical trials, predictive toxicology plays a crucial role in identifying potential adverse effects before clinical trials by the combination of computational technologies and experimental designs. The in vitro and in vivo systems from traditional approaches are now being supplemented with quantum mechanics (QM) and rational drug design (RDD), which have markedly advanced toxicity prediction. Identifying reactive metabolites and toxicity pathways is aided by QM's atomic-level analysis of molecular interactions. To maximize effectiveness and reduce side effects, RDD uses a drug design that combines structures and functions. This article reviews the QM and RD approach to predictive toxicology with a focus on the need for stronger integration of both technologies to increase the safety of neurological drugs. Improvements in drug prediction in toxicology may be provided by the further development of AI modeling and quantum mechanical simulations in the future.

AUTHOR'S AFFILIATION:

[1] Amity Institute of Biotechnology, Amity University, Lucknow, Uttar Pradesh, India.

[2] Associate Professor, Amity Institute of Biotechnology, Amity University, Lucknow, Uttar Pradesh, India.

CORRESPONDING AUTHOR:

Prachi Srivastava, Associate Professor, Amity Institute of Biotechnology, Amity University, Lucknow, Uttar Pradesh, India.

E-mail: psrivastava@amity.edu

➢ **Received:** 12-03-2025 ➢ **Accepted:** 25-04-2025

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-Commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the Red Flower Publication and Open Access pages (https://www.rfppl.co.in)

KEYWORDS

• Neurological disorders • Predictive toxicology • Quantum mechanics (QM) • Rational drug design (RDD) • Toxicity prediction • Neurotoxicity • Computational modeling • AI in drug discovery

Key message: Toxicity assessment in neurological drug development is enhanced by predictive toxicology, integrating quantum mechanics (QM) and rational drug design (RDD), reducing late-stage failures. Strengthening QM-RDD synergy can improve drug safety, with future advancements in AI and quantum simulations offering further predictive accuracy.

INTRODUCTION

Disorders like Parkinson's, epilepsy and multiple sclerosis are major health and economic burdens. The process of drug development is impeded by high attrition rates from promise of efficacy to the latter stages due to various reasons such as neurotoxicity, hepatotoxicity, and cardiotoxicity.[1] Traditional in vitro and in vivo models are expensive and slow, often inaccurate due to the differences between species. Predictive toxicology utilizes quantum mechanics (QM) and rational drug design (RDD) to augment the accuracy of toxicity prediction and the safety evaluation of drugs.[2] While QM predicts the possibility of toxic metabolite RDD creates fewer toxic drugs. This work addresses the interaction of QM and RDD in neuropharmaceuticals and predicts the development of safer neuropharmaceuticals - clinical trials of drugs for the treatment of disorders.[3]




Figure 1: This figure here provides some common toxicity endpoints that are assessed in drug discovery and safety evaluation

REVIEW OF LITERATURE

Introduction to Predictive Toxicology in Neurological Disorder Drugs

Predictive toxicology is critical in the process of drug discovery and development above everything else when it comes to specific neurological disorders, where the compounds safety and efficacy is of the highest importance. The drugs for neurological disorders often deal with complex cross talks within the central nervous system (CNS), which makes

them vulnerable to any unwanted toxic side effects[4]. Established and routine practices of toxicological studies are mainly based on in vivo and in vitro models which are increasingly proving to be inadequate due to ethical issues, high expenses, and absence of human reliabilities[5]. It has been reported that approximately 90% of medications that target the CNS are unsuccessful in clinical trials, with 30–40% of those failures concerning safety and the drug's associated toxicity[6]. As a result, In silico quantum mechanics and rational drug design approaches are becoming more popular for the purposes of predicting the toxicity of the drug within a greater margin of safety and decreasing the chances of failure in the advanced stages of drug development[7].

Quantum Mechanics and Its Role in Toxicity Prediction

Quantum mechanics applied in medical chemistry helps in the interpretation of the molecular activities of certain biological compounds, which is very important when evaluating the toxicity of some drugs directed to the nervous system[8]. Theories like the Density Functional Theory (DFT) and Hartree-Fock (HF) and their derivatives take care of charge distribution in molecules, molecular reactivity, and stabilization of the molecule. These parameters are important in determining the action of the drug on the biological systems, for example, binding to neurotransmitter receptors or metabolic enzymes[9].

In this paper, a DFT study of 50 active neurochemical compounds is reported. It was found that 30% of the molecules of the compounds studied have high electrophile index and are candidates for oxidative stress neurotoxic[10]. Moreover, QM estimates of binding energy of some neurological drugs have been done and it was found out that compounds with binding energy lesser than –9.0 kcal/mol tend to be less neurotoxic[11].

The most recent research proves that approaches employing quantum mechanical methods have managed to compute the binding affinities of specific neuro substances to N-methyl-D-aspartate (NMDA) and gamma-aminobutyric acid (GABA) receptors. By analyzing molecular orbitals and the distribution of charges, the methods succeed in selecting compounds with high specificity and low off-target activity[12].

Rational Drug Design for Reducing Neurological Drug Toxicity

The implementation of rational design lacks experimentation, and it uses powerful reasoning to create new compounds with the desired therapeutic effects and non-existing toxicity. It's a blend of computer-aided analysis, artificial intelligence, and SAR for lead compound identification and modification. Rational drug design helps develop and optimize medicines for neurology and sidestep severe consequences like hepatotoxic, cardiotoxic, and neurotoxic effects[13].

The integration of machine learning tools to estimate toxicity endpoints is one of the greatest feats of innovation in drug design. AI models able to predict potential toxicity examine a plethora of chemical structures with their relevant datasets regarding toxicity. Some studies that employ AI-based predictive models have demonstrated significant progress in identifying potentially neurotoxic compounds prior to preclinical testing, showing promising result for improving drug development efficiency[14].

On the other hand, molecular docking alongside molecular dynamics simulation is just as important in rational drug design because they study drug-target interactions on the molecular level. These techniques provide insight into possible neurotoxic effects of drugs by understanding how a drug interacts with its intended target and whether it does something else that is not supposed to be done[15]. For instance, in a study molecular dynamic and docking simulations to investigate the interaction of neurotoxins with human voltage-gated sodium channels, highlighting the importance of such interactions in neurotoxicity[16].

Predictive Models and Toxicity Endpoints in Neurological Drug Development

Quantitative Structure-Activity Relationship (QSAR) Models

Statistical and machine learning techniques are used in QSAR models to relate biological activities to chemical structures which later on predict harmful effects even before an experiment is conducted[17]. The process starts with the chemical structures and toxicity information being procured from cheminformatics repositories like ToxCast

and Tox21. After that, the technique of feature engineering is used to extract molecular characteristics that are crucial for drug metabolism, like solubility, logP, and Lipinski's rule of five. The constructed features are used for model development, in which different regression and classification techniques are applied, such as Random Forests, Support Vector Machines (SVM), and Neural Networks. In the end, the models are used for validation and prediction in which the model is cross-validated with the experimental data sets[18,19]. Common tools that rely on QSAR models include deep learning models for predictive toxicology - DeepTox trained on Tox21 data claims high prediction accuracy for various toxic effects. There is also the multi-purpose VEGA QSAR model that combines several existing QSAR models for the prediction of neurotoxic, hepatotoxic, and carcinogenic effects, along with the OECD Toolbox that applies structural alerts and read-across features for QSAR prediction[20].

Adverse Outcome Pathway (AOP) Framework

The AOP (Adverse Outcome Pathway) provides a clear description of health impacts triggered by certain molecular and cellular actions. It combines high-throughput screening (HTS) data, computational models, and biological pathway analysis to determine if something is potentially neurotoxic[21]. The process starts with the consideration of Molecular Initiating Events (MIEs), which include receptor binding and enzyme inhibition, and other upstream events. These MIEs are connected to Key Events (KEs) at the level of the cell, tissue, and organ, forming a mechanistic pathway to toxicity. Consequently, the AOP framework determines the Adverse Outcome (AO), which is how the drug's ability to cause neurotoxic is evaluated by correlating the molecular changes with clinical signs of the illness. AOP model validation testes and simulation use are in vitro assays and in silico shifting some of the primary dependence away from animal testing and providing more accurate exposures and estimates of neurotoxicity[22].

In-silico tools for toxicity prediction

The prognosis of multiple toxicity endpoints in silico as far as drug discovery is concerned, for example, carcinogenicity, mutagenicity, hepatotoxicity, and neurotoxicity is made simpler due to the availability of various advanced in silico methods. DEREK Nexus achieves neurotoxicity prediction sensitivity of 78 % through a rule based structural alert system[23]. ProTox-II employs machine learning and similarity and first takes input in structure form, then adds descriptors and uses ML models for classification. This results in a lot sensitivity for neuroactive compounds[24].

Table 1: This table presents widely used tools, their predicted endpoints, and the methodologies employed for prediction

S. no.	Tools	Endpoints	Methodology	References
1.	ProTox3.0	Neurotoxicity, Hepatotoxicity, BBB toxicity	AI-based toxicity prediction, molecular docking	25
2.	ToxTree	Neurotoxicity, Carcinogenicity, Mutagenicity, Hepatotoxicity, Immunotoxicity	Rule-based structural alerts	26
3.	pKCS	Hepatotoxicity, Mutagenicity	QSAR model, machine learning	27
4.	vNN	Mutagenicity, Carcinogenicity, Skin sensitization	Deep learning on chemical datasets	28
5.	ADMET lab 3.0	Hepatotoxicity, Nephrotoxicity, Cardiotoxicity	QSAR, ML, knowledge-based models	29
6.	eMolTox	Neurotoxicity, Hepatotoxicity, Nephrotoxicity, Carcinogenicity	ML models (SVM, random forests)	30
7.	Ames Test	Mutagenicity	Bacterial assay for DNA mutation detection	31

Challenges in Predictive Toxicology

Blood-Brain Barrier (BBB) Limitations

The blood-brain barrier (BBB) is an important protective layer for the Central Nervous System (CNS), but the current in silico models of BBB permeability only achieve about 78% accuracy. This falls short of what is needed to accurately predict neurotoxicity[32]. Newer models combining physiologically based pharmacokinetics (PBPK) with molecular dynamics (MD) simulations have achieved almost 85% accuracy, but these models are expensive to run and need additional work[33].

Lack of High-Quality Toxicity Datasets

The efficacy of models designed to predict toxicity largely relies on the availability of well-structured annotated datasets. However, ToxCast, Tox21, and many other public datasets exhibit variability due to differences in design and annotation quality or incomplete coverage[34]. The analysis of 20,000 compounds in various databases disclosed that variation across databases caused average prediction differences of 12-18% in neurotoxicity classification[35].

Computational Cost of Quantum Mechanics (QM)-Based Approaches

Models that are based on quantum mechanics (QM) are unmatched in their accuracy when modeling electronic interactions and oxidative stress-related toxic effects. However, when it comes to our drug screening processes, it can be challenging due to high computational requirements. In contrast, traditional QSAR models tend to process thousands of compounds in just minutes, but yield results with lower accuracy[36]. More optimization needs to be done to accomplish a balance between accuracy and efficiency for large-scale neurotoxicity spectrum predictions.

Future Directions in Predictive Toxicology

Multi-Omics Integration (Genomics, Transcriptomics, Proteomics)

The integration of various techniques, such as genomics, transcriptomics, and proteomics, is improving the prediction of neurotoxicity since it exposes the molecular changes associated with toxicity[37]. From profiling neuroactive compounds, predictive accuracy for neurotoxicity has been achieved. Glial fibrillary acidic protein (GFAP) and Neurofilament light (NfL) proteomic biomarkers correlate with neuro-damage.

Hybrid Models Combining AI and QM

The hybrid QSAR-QM model allows for the combining of artificial intelligence founded QSAR models with quantum mechanics techniques in an efficient and precise manner. Deep learning integrated QM models are capable of reducing the computational cost of DFT calculations, thus increasing the model efficiency for expansive preliminary evaluations[39].

CONCLUSION

To summarize, the prediction of toxic compounds is indeed very important for the development of drugs for most of neurological disorders. In many cases, advanced methods are necessary because the classical techniques are time-consuming and costly. QM and RDD have sufficient molecular information to predict toxicity at an early stage of drug development, which makes the entire process of drug formulation less hazardous. Models based on QM, like DFT, can provide analytical toxicity estimates by evaluating an object's electronic structure and reactivity. These techniques, coupled with machine learning algorithms and other in silico approaches increase the productivity of drug screening. Efficacy and safety are considered together at the moment when the drug is designed with the help of RDD and other computer-based techniques.

However, there are problems like the complexity of computation and insufficient testing is still there. To solve these problems, there is a need for progress made in AI assisted modeling as well as interdisciplinary approaches. Combining QM, RDD, and big data analytics will improve drug discovery pipelines by strengthening predictive toxicity frameworks. The application of QM and RDD can produce drugs for neurological disorders that are much safer and more effective while keeping the risk of toxicity to a minimum. In the future, work should be done to advance the precision of the model, get acceptance from relevant authorities, and increase the range of applicable chemical compounds.

Conflict of Interest: The authors declare no conflicts of interest related to this study.

REFERENCES

1. Otieno, M.A., & Lehman-McKeeman, L. D. (2010). Mechanism-based toxicity studies for drug development. In J. J. Xu & L. Urban (Eds.), Predictive Toxicology in Drug Safety (pp. 230–243). chapter, Cambridge: Cambridge University Press.
2. Silva-junior, Edeildo& Araújo-Júnior, João & Aquino, Thiago. (2017). Quantum mechanical (QM) calculations applied to ADMET drug prediction: A review. Current Drug Metabolism. 18. 1-1. 10.2174/1389200218666170316094514.
3. Geerts H, Wikswo J, van der Graaf PH, Bai JPF, Gaiteri C, Bennett D, Swalley SE, Schuck E, Kaddurah-Daouk R, Tsaioun K, Pelleymounter M. Quantitative Systems Pharmacology for Neuroscience Drug Discovery and Development: Current Status, Opportunities, and Challenges. CPT Pharmacometrics SystPharmacol. 2020 Jan;9(1):5-20. doi: 10.1002/psp4.12478. Epub 2019 Nov 24. PMID: 31674729; PMCID: PMC6966183.
4. Townsend, Piers A. and Grayson, Matthew N.. 2020. "Density Functional Theory in the Prediction of Mutagenicity: A Perspective". American Chemical Society. https://doi.org/10.1021/acs.chemrestox.0c00113
5. Pognan, F., Beilmann, M., Boonen, H. C. M., Czich, A., Dear, G., Hewitt, P., Mow, T., Oinonen, T., Roth, A., Steger-Hartmann, T., Valentin, J. P., Van Goethem, F., Weaver, R. J., & Newham, P. (2023). The evolving role of investigative toxicology in the pharmaceutical industry. Nature reviews. Drug discovery, 22(4), 317–335. https://doi.org/10.1038/s41573-022-00633-x
6. Sun, D., Gao, W., Hu, H., & Zhou, S. (2022). Why 90% of clinical drug development fails and how to improve it?. Acta pharmaceutica Sinica. B, 12(7), 3049–3062. https://doi.org/10.1016/j.apsb.2022.02.002
7. Raies, A. and Bajic, V.. 2016. "In silico toxicology: computational methods for the prediction of chemical toxicity". Wiley Interdisciplinary Reviews. Computational Molecular Science. https://doi.org/10.1002/wcms.1240
8. Arodola, Olayide& Soliman, Mahmoud. (2017). Quantum mechanics implementation in drug-design workflows: does it really help?. Drug Design, Development and Therapy. 11. 2551-2564. 10.2147/DDDT.S126344.
9. S. Atrushi, K. , M. Ameen, D. , H. Abdulrahman, S. and T. Abachi, F. (2023). Density Functional Theory, ADME, and Molecular Docking of Some Anthranilic Acid Derivatives as Cyclooxygenase Inhibitors. Journal of Medicinal and Chemical Sciences, 6(9), 1943-1952. doi: 10.26655/JMCHEMSCI.2023.9.3
10. Sayre, L. M., Perry, G., & Smith, M. A. (2008). Oxidative stress and neurotoxicity. Chemical research in toxicology, 21(1), 172–188. https://doi.org/10.1021/tx700210j
11. Makhaeva, G. F., Kovaleva, N. V., Rudakova, E. V., Boltneva, N. P., Lushchekina, S. V., Astakhova, T. Y., Timokhina, E. N., Serebryakova, O. G., Shchepochkin, A. V., Averkov, M. A., Utepova, I. A., Demina, N. S., Radchenko, E. V., Palyulin, V. A., Fisenko, V. P., Bachurin, S. O., Chupakhin, O. N., Charushin, V. N., & Richardson, R. J. (2023). Derivatives of 9-phosphorylated acridine as butyrylcholinesterase inhibitors with antioxidant activity and the ability to inhibit β-amyloid self-aggregation: potential therapeutic agents for Alzheimer's disease. Frontiers in pharmacology, 14, 1219980. https://doi.org/10.3389/fphar.2023.1219980
12. Dalangin, R., Kim, A., & Campbell, R. E. (2020). The Role of Amino Acids in Neurotransmission and Fluorescent Tools for Their Detection. International journal of molecular sciences, 21(17), 6197. https://doi.org/10.3390/ijms21176197
13. Paul, D., Sanap, G., Shenoy, S., Kalyane, D., Kalia, K., & Tekade, R. K. (2021). Artificial intelligence in drug discovery and development. Drug discovery today, 26(1), 80–93. https://doi.org/10.1016/j.drudis.2020.10.010
14. Yang, S., & Kar, S. (2023). Application of artificial intelligence and machine learning in early detection of adverse drug reactions (ADRs) and drug-induced toxicity. Artificial Intelligence Chemistry, 1(2), 100011. https://doi.org/10.1016/j.aichem.2023.100011
15. Lemkul, J. A., & Bevan, D. R. (2012). The role of molecular simulations in the development of inhibitors of amyloid β-peptide aggregation for the treatment of Alzheimer's disease. ACS chemical neuroscience, 3(11), 845–856. https://doi.org/10.1021/cn300091a
16. Saini V, Sween, Vishal, Dang AS, Kumar A (2016) Molecular Dynamics and Docking Simulation Studies of Human Voltage Gated Sodium Channel against Neurotoxins. J Drug

Des Res 3(1): 1022.

17. Peter, S. C., Dhanjal, J. K., Malik, V., Radhakrishnan, N., Jayakanthan, M., & Sundar, D. (2018). Quantitative Structure-Activity Relationship (QSAR): Modeling Approaches to Biological Applications. Encyclopedia of Bioinformatics and Computational Biology, 661-676. https://doi.org/10.1016/B978-0-12-809633-8.20197-0

18. Capuzzi, S. J., Politi, R., Isayev, O., Farag, S., &Tropsha, A. (2016). QSAR Modeling of Tox21 Challenge Stress Response and Nuclear Receptor Signaling Toxicity Assays. Frontiers in Environmental Science, 4, 170957. https://doi.org/10.3389/fenvs.2016.00003

19. Wu, L., Huang, R., Tetko, I. V., Xia, Z., Xu, J., & Tong, W. (2021). Trade-off Predictivity and Explainability for Machine-Learning Powered Predictive Toxicology: An in-Depth Investigation with Tox21 Data Sets. Chemical research in toxicology, 34(2), 541–549. https://doi.org/10.1021/acs.chemrestox.0c00373

20. Mayr, A., Klambauer, G., Unterthiner, T., & Hochreiter, S. (2016). DeepTox: Toxicity Prediction using Deep Learning. Frontiers in Environmental Science, 3, 167215. https://doi.org/10.3389/fenvs.2015.00080

21. Bal-Price, A., & Meek, M. E. B. (2017). Adverse outcome pathways: Application to enhance mechanistic understanding of neurotoxicity. Pharmacology & therapeutics, 179, 84–95. https://doi.org/10.1016/j.pharmthera.2017.05.006

22. Fay, K. A., Villeneuve, D. L., LaLone, C. A., Song, Y., Tollefsen, K. E., & Ankley, G. T. (2017). Practical approaches to adverse outcome pathway development and weight-of-evidence evaluation as illustrated by ecotoxicological case studies. Environmental toxicology and chemistry, 36(6), 1429–1449. https://doi.org/10.1002/etc.3770

23. Serafini, M. M., Sepehri, S., Midali, M., Stinckens, M., Biesiekierska, M., Wolniakowska, A., Gatzios, A., Rundén-Pran, E., Reszka, E., Marinovich, M., Vanhaecke, T., Roszak, J., Viviani, B., &SenGupta, T. (2024). Recent advances and current challenges of new approach methodologies in developmental and adult neurotoxicity testing. Archives of toxicology, 98(5), 1271–1295. https://doi.org/10.1007/s00204-024-03703-8

24. Banerjee, P., Eckert, A. O., Schrey, A. K., & Preissner, R. (2018). ProTox-II: A webserver for the prediction of toxicity of chemicals. Nucleic Acids Research, 46(W1), W257-W263. https://doi.org/10.1093/nar/gky318

25. Banerjee, P., Kemmler, E., Dunkel, M., & Preissner, R. (2024). ProTox 3.0: a webserver for the prediction of toxicity of chemicals. Nucleic acids research, 52(W1), W513–W520. https://doi.org/10.1093/nar/gkae303

26. Bhat, V., & Chatterjee, J. (2021). The Use of In Silico Tools for the Toxicity Prediction of Potential Inhibitors of SARS-CoV-2. Alternatives to laboratory animals : ATLA, 49(1-2), 22–32. https://doi.org/10.1177/02611929211008196

27. Wilson, A., Grabowski, P., Elloway, J., Ling, S., Stott, J., & Doherty, A. (2021). Transforming early pharmaceutical assessment of genotoxicity: applying statistical learning to a high throughput, multi end point in vitro micronucleus assay. Scientific reports, 11(1), 2535. https://doi.org/10.1038/s41598-021-82115-5

28. Hao, Y., Romano, J. D., & Moore, J. H. (2022). Knowledge-guided deep learning models of drug toxicity improve interpretation. Patterns, 3(9), 100565. https://doi.org/10.1016/j.patter.2022.100565

29. Wei, Y., Palazzolo, L., Ben Mariem, O., Bianchi, D., Laurenzi, T., Guerrini, U., &Eberini, I. (2024). Investigation of in silico studies for cytochrome P450 isoforms specificity. Computational and structural biotechnology journal, 23, 3090–3103. https://doi.org/10.1016/j.csbj.2024.08.002

30. Jain, S., Siramshetty, V. B., Alves, V. M., Muratov, E. N., Kleinstreuer, N., Tropsha, A., Nicklaus, M. C., Simeonov, A., & Zakharov, A. V. (2021). Large-Scale Modeling of Multispecies Acute Toxicity End Points Using Consensus of Multitask Deep Learning Methods. Journal of chemical information and modeling, 61(2), 653–663. https://doi.org/10.1021/acs.jcim.0c01164

31. Guy, R. C. (2023). Ames test. Encyclopedia of Toxicology (Fourth Edition), 377-379. https://doi.org/10.1016/B978-0-12-824315-2.01101-5

32. Kumar, R., Sharma, A., Alexiou, A., Bilgrami, A. L., Kamal, M. A., & Ashraf, G. M. (2022). DeePred-BBB: A Blood Brain Barrier Permeability Prediction Model With Improved Accuracy. Frontiers in Neuroscience, 16, 858126. https://doi.org/10.3389/fnins.2022.858126

33. Chen, A., Yarmush, M. L., & Maguire, T. (2012). Physiologically based pharmacokinetic models: integration of in silico approaches with micro cell culture analogues. Current drug metabolism, 13(6), 863–880. https://doi.

org/10.2174/138920012800840419

34. Richard, A. M., Tao, D., LeClair, C. A., Leister, W., Tretyakov, K. V., White, E., 5th, Lewis, K. C., Sefler, A., Shinn, P., Collins, B. J., Nguyen, D. T., Ye, L., Zhao, T., Xu, T., Williams, A. J., Waidyanatha, S., Thomas, R. S., Tice, R., Simeonov, A., & Huang, R. (2025). Analytical Quality Evaluation of the Tox21 Compound Library. Chemical research in toxicology, 38(1), 15–41. https://doi.org/10.1021/acs.chemrestox.4c00330

35. Crofton, K. M., Bassan, A., Behl, M., Chushak, Y. G., Fritsche, E., Gearhart, J. M., Marty, M. S., Mumtaz, M., Pavan, M., Ruiz, P., Sachana, M., Selvam, R., Shafer, T. J., Stavitskaya, L., Szabo, D. T., Szabo, S. T., Tice, R. R., Wilson, D., Woolley, D., & Myatt, G. J. (2022). Current status and future directions for a neurotoxicity hazard assessment framework that integrates in silico approaches. Computational toxicology (Amsterdam, Netherlands), 22, 100223. https://doi.org/10.1016/j.comtox.2022.100223

36. Sliwoski, G., Kothiwale, S., Meiler, J., & Lowe, E. W., Jr (2013). Computational methods in drug discovery. Pharmacological reviews, 66(1), 334–395. https://doi.org/10.1124/pr.112.007336

37. Min, E. K., Lee, A. N., Lee, J. Y., Shim, I., Kim, P., Kim, T. Y., Kim, K. T., & Lee, S. (2021). Advantages of omics technology for evaluating cadmium toxicity in zebrafish. Toxicological research, 37(4), 395–403. https://doi.org/10.1007/s43188-020-00082-x

38. Pattnaik, Punyaslok& Raghunathan, Shampa & Kalluri, Subrahmanya & Bhimalapuram, Prabhakar & Jawahar, Cheerakkuzhi&Priyakumar, U.. (2020). Machine Learning for Accurate Force Calculations in Molecular Dynamics Simulations. The Journal of Physical Chemistry A. XXXX. 10.1021/acs.jpca.0c03926.

39. Ju, F., Wei, X., Huang, L., Jenkins, A. J., Xia, L., Zhang, J., Zhu, J., Yang, H., Shao, B., Dai, P., Williams-Young, D. B., Mayya, A., Hooshmand, Z., Efimovskaya, A., Baker, N. A., Troyer, M., & Liu, H. (2024). Acceleration without Disruption: DFT Software as a Service. Journal of chemical theory and computation, 20(24), 10838–10851. https://doi.org/10.1021/acs.jctc.4c00940